Table 4.
Network based repurposing studies using gene regulatory networks, DTI, Drug–disease, and side-effect association.
Study name | Method | Datasets | Evaluation criteria | |
---|---|---|---|---|
Gene regulatory networks and Gene expression Data | ||||
1 | DTI prediction for repositioning [113] | Network propagation, scoring based on neighborhood, random walks | GEO repository for Gene expression data | AUC - ROC |
2 | A network flow approach for repurposing with case study on prostate cancer [115] | Maximum Flow | OMIM, KEGG, PGDB, DrugBank | Precision, Mean, Position |
3 | NFFinder [119] | Statistical method for analysis | Cmap, DrugMatrix, and GEO | – |
4 | System biology approach developed by a novel knowledge-driven method [121] | Bayesian network-based approach | Gene-gene interaction | – |
5 | Functional Module Method with case study of Prostate Cancer [145] | Functional linkage network | TCGA, LINCS, GEO, OMIM | AUC - ROC |
6 | computational DR using Kolmogorov– Smirnov enrichment testing for [123] | Enrichment (Kolmogorov–Smirnov) | GEO and CTD | – |
Protein–protein interaction networks | ||||
7 | Network Analysis for potential DTI identification [146] | SVM, Logistic regression, L1-regularization, KNN | STRING, DrugBank, Gene cards | Z score and Standard deviation |
8 | Comprehension of Complex disease using PPIN [112] | – | Gene expression omnibus (GEO) | Harmonic mean and Precision |
9 | Drug repurposing shared network of PPIs and genes [147] | Similarity | STRING and DrugBank | – |
10 | PPINs and MMP cellular model [148] | Cross talk by analysis of betweenness centrality | KEGG, OMIM and iRef Index database | – |
Drug–target interactions | ||||
11 | DTI prediction using Probabilistic soft logic [135] | Soft probabilistic logic | DrugBank, KEGG, DCDB, and Matador | AUC, Precision, AUPR |
12 | Network-based inference for prediction of DTI [136] | – | DrugBank | AUC and Precision |
13 | Bayesian matrix factorization-based DTI prediction[111] | Prediction based on Bayesian algorithm | DrugBank and DTIs | AUC |
14 | DTI prediction from integration of chemical and genomic spaces [138] | Bi-partite graph ML | DrugBank and DTIs | AUC |
15 | Bipartite model for DTI prediction [139] | Supervised method of network inference | DrugBank and DTIs | AUC-ROC, AUPR |
Drug–disease and side-effect association | ||||
16 | Drug repositioning methods based on network inference [149] | – | CTD | AUC-ROC |
17 | PREDICT, a method to infer the new indications [44] | Logistic regression | DrugBank, SIDER, KEGG (Drug), DCDB, Expression Atlas, OMIM | AUC, precision |
18 | Clustering of Heterogeneous networks to repurpose the drugs [150] | Clustering | NCBI Gene, KEGG Medicus | – |
19 | Use of Side effects in Network based approaches to drug repurposing [151] | Statistical analysis | SIDER, FDA approved drugs | – |